中国糖尿病杂志
中國糖尿病雜誌
중국당뇨병잡지
CHINESE JOURNAL OF DIABETES
2011年
1期
55-59
,共5页
矫杰%李雅君%李晓沛%张彦%蔡瑾
矯傑%李雅君%李曉沛%張彥%蔡瑾
교걸%리아군%리효패%장언%채근
罗格列酮%非酒精性脂肪性肝炎%肝纤维化%大鼠
囉格列酮%非酒精性脂肪性肝炎%肝纖維化%大鼠
라격렬동%비주정성지방성간염%간섬유화%대서
Rosiglitazone%Nonalcoholic steatohepatitis% Hepatic fibrosis% Rats
目的 观察罗格列酮预防非酒精性脂肪性肝炎(NASH)大鼠肝纤维化的作用.方法 建立SD大鼠NASH伴肝纤维化的模型(HF24W),同时高脂喂养大鼠12周后予罗格列酮(1.5mg·kg-1·d-1)干预12周(HF24W+RGZ12W组).观察肝组织病理学改变,测定血清丙二醛(MDA)、肿瘤坏死因-α(TNF-α)、游离脂肪酸(FFA)、Ins、FPG,并计算胰岛素抵抗指数(HOMA-IR).结果 HF24W+RGZ12W组肝组织炎症、纤维化评分明显低于HF24W组(P＜0.05),脂肪变性与HF24W组无统计学差异;HF24W+RGZ12W组血清MDA、TNF-α、FFA、Ins、HOMA-IR均明显低于HF24W组(P＜0.05).结论 罗格列酮可以减缓NASH大鼠肝纤维化的发生发展.
目的 觀察囉格列酮預防非酒精性脂肪性肝炎(NASH)大鼠肝纖維化的作用.方法 建立SD大鼠NASH伴肝纖維化的模型(HF24W),同時高脂餵養大鼠12週後予囉格列酮(1.5mg·kg-1·d-1)榦預12週(HF24W+RGZ12W組).觀察肝組織病理學改變,測定血清丙二醛(MDA)、腫瘤壞死因-α(TNF-α)、遊離脂肪痠(FFA)、Ins、FPG,併計算胰島素牴抗指數(HOMA-IR).結果 HF24W+RGZ12W組肝組織炎癥、纖維化評分明顯低于HF24W組(P＜0.05),脂肪變性與HF24W組無統計學差異;HF24W+RGZ12W組血清MDA、TNF-α、FFA、Ins、HOMA-IR均明顯低于HF24W組(P＜0.05).結論 囉格列酮可以減緩NASH大鼠肝纖維化的髮生髮展.
목적 관찰라격렬동예방비주정성지방성간염(NASH)대서간섬유화적작용.방법 건립SD대서NASH반간섬유화적모형(HF24W),동시고지위양대서12주후여라격렬동(1.5mg·kg-1·d-1)간예12주(HF24W+RGZ12W조).관찰간조직병이학개변,측정혈청병이철(MDA)、종류배사인-α(TNF-α)、유리지방산(FFA)、Ins、FPG,병계산이도소저항지수(HOMA-IR).결과 HF24W+RGZ12W조간조직염증、섬유화평분명현저우HF24W조(P＜0.05),지방변성여HF24W조무통계학차이;HF24W+RGZ12W조혈청MDA、TNF-α、FFA、Ins、HOMA-IR균명현저우HF24W조(P＜0.05).결론 라격렬동가이감완NASH대서간섬유화적발생발전.
ObjectiveTo investigate the therapeutic efficacy of rosiglitazone in prevention of hepatic fibrosis in rats with nonalcoholic steatohepatitis(NASH). MethodsThe high fat diet-induced NASH rats model with fibrosis were established(Group HF24W). The NASH rats fed for 12 weeks on higt-fat diet were further treated with rosiglitazone(15mg?kg-1?d-1) for 12 weeks(Group HF24W+RGZ12W). Histological changes in liver tissue in all groups were observed by HE staining and Masson staining. The levels of malondialdehyde(MDA)，tumor necrosis factor-α(TNF-α)， free fatty acid(FFA)，insulin(Ins) and fasting plasma glucose(FPG) in sera were measured respectively. Insulin resistance index(HOMA-IR) were calculated. ResultsThe semi-quantification of inflammation and fibrosis were significantly lower in group HF24W+RGZ12W than in group HF24W (529±256 vs 1275±359;550±138 vs 1180±110，P<005). There was no difference in fat accumulation in hepatic tissue between group HF24W+RGZ12W and group HF24W(P>005).The levels of MDA， TNF-α， FFA， INS，HOMA-IR were significantly lower in group HF24W+RGZ12W than in group HF24W(3408±1135 vs 1237±616;1346±170 vs 1044±172， 054±009 vs 019±008;4157±1030 vs 2450±371;1293±365 vs 716±093，P<005). ConclusionsRosiglitazone could retard the occurrence and progression of hepatic fibrosis in rats with NASH.
